If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> UROLOGY<br /> ISSN 2053-4213 Vol 3.2 • May 2015 • emjreviews.com<br /> INSIDE<br /> Review of<br /> EAU 2015<br /> Madrid, Spain<br /> CONTENTS<br /> EDITORIAL BOARD......................................................................................................................................... 4<br /> CONGRESS REVIEW........................................................................................................................................ 12<br /> • Review of the European Association of Urology Congress held in Madrid, Spain,<br /> 20th-24th March 2015<br /> INTERVIEWS WITH EMJ UROLOGY EDITORIAL BOARD....................................................................... 33<br /> SYMPOSIUM REVIEWS<br /> • A NEW APPROACH FOR THE PATIENT WITH ERECTILE DYSFUNCTION................................... 48<br /> • NAVIGATING THE mCRPC LANDSCAPE: E<a title="EMJ Urology 3.2 2015 page 1" href="http://viewer.zmags.com/publication/565ee22c?page=1"> UROLOGY ISSN 2053-4213 </a> <a title="EMJ Urology 3.2 2015 page 2" href="http://viewer.zmags.com/publication/565ee22c?page=2"> CONTENTS EDITORIAL BOARD.......................</a> <a title="EMJ Urology 3.2 2015 page 3" href="http://viewer.zmags.com/publication/565ee22c?page=3"> UROLOGY • CHEMOTHERAPY AND NEW DRUGS IN PROSTAT</a> <a title="EMJ Urology 3.2 2015 page 4" href="http://viewer.zmags.com/publication/565ee22c?page=4"> Editorial Board Editor-in-Chief: Dr Abdullah E</a> <a title="EMJ Urology 3.2 2015 page 5" href="http://viewer.zmags.com/publication/565ee22c?page=5"> Urology Dr Ali Serdar Gözen, Assistant Doctor</a> <a title="EMJ Urology 3.2 2015 page 6" href="http://viewer.zmags.com/publication/565ee22c?page=6"> </a> <a title="EMJ Urology 3.2 2015 page 7" href="http://viewer.zmags.com/publication/565ee22c?page=7"> European Medical Journal EMJ Urology Vol 3.2 Ma</a> <a title="EMJ Urology 3.2 2015 page 8" href="http://viewer.zmags.com/publication/565ee22c?page=8"> Use the NMIBC Toolbox Run the Guidelines </a> <a title="EMJ Urology 3.2 2015 page 9" href="http://viewer.zmags.com/publication/565ee22c?page=9"> Welcome Hello and welcome to the second editio</a> <a title="EMJ Urology 3.2 2015 page 10" href="http://viewer.zmags.com/publication/565ee22c?page=10"> 18th ECCO - 40th ESMO E</a> <a title="EMJ Urology 3.2 2015 page 11" href="http://viewer.zmags.com/publication/565ee22c?page=11"> Foreword Dr A. Erdem Canda </a> <a title="EMJ Urology 3.2 2015 page 12" href="http://viewer.zmags.com/publication/565ee22c?page=12"> EAU ANNUAL CONGRESS 2015 IFEMA - FERIA DE MADRID</a> <a title="EMJ Urology 3.2 2015 page 13" href="http://viewer.zmags.com/publication/565ee22c?page=13"> Welcome to the European Medical Journal</a> <a title="EMJ Urology 3.2 2015 page 14" href="http://viewer.zmags.com/publication/565ee22c?page=14"> EAU ANNUAL CONGRESS 2015 “When I took this positi</a> <a title="EMJ Urology 3.2 2015 page 15" href="http://viewer.zmags.com/publication/565ee22c?page=15"> H IGHLIGHTS Combining MRI with Conven</a> <a title="EMJ Urology 3.2 2015 page 16" href="http://viewer.zmags.com/publication/565ee22c?page=16"> EAU ANNUAL CONGRESS 2015 of PSA and MRI compared</a> <a title="EMJ Urology 3.2 2015 page 17" href="http://viewer.zmags.com/publication/565ee22c?page=17"> potential predictive role for this clinical </a> <a title="EMJ Urology 3.2 2015 page 18" href="http://viewer.zmags.com/publication/565ee22c?page=18"> EAU ANNUAL CONGRESS 2015 comprehensive hi</a> <a title="EMJ Urology 3.2 2015 page 19" href="http://viewer.zmags.com/publication/565ee22c?page=19"> that period, implying the need for a comorbidity </a> <a title="EMJ Urology 3.2 2015 page 20" href="http://viewer.zmags.com/publication/565ee22c?page=20"> EAU ANNUAL CONGRESS 2015 </a> <a title="EMJ Urology 3.2 2015 page 21" href="http://viewer.zmags.com/publication/565ee22c?page=21"> Thus, while 49 patients (23.3% of respondent</a> <a title="EMJ Urology 3.2 2015 page 22" href="http://viewer.zmags.com/publication/565ee22c?page=22"> EAU ANNUAL CONGRESS 2015 These data should ho</a> <a title="EMJ Urology 3.2 2015 page 23" href="http://viewer.zmags.com/publication/565ee22c?page=23"> Lead researcher Dr Maarten de Rooij, Department </a> <a title="EMJ Urology 3.2 2015 page 24" href="http://viewer.zmags.com/publication/565ee22c?page=24"> EAU ANNUAL CONGRESS 2015 With im</a> <a title="EMJ Urology 3.2 2015 page 25" href="http://viewer.zmags.com/publication/565ee22c?page=25"> “We have shown that cases of BLC can be identified</a> <a title="EMJ Urology 3.2 2015 page 26" href="http://viewer.zmags.com/publication/565ee22c?page=26"> EAU ANNUAL CONGRESS 2015 Hexvix®-Guided</a> <a title="EMJ Urology 3.2 2015 page 27" href="http://viewer.zmags.com/publication/565ee22c?page=27"> treatment approaches in non-muscle invasive BLC. </a> <a title="EMJ Urology 3.2 2015 page 28" href="http://viewer.zmags.com/publication/565ee22c?page=28"> EAU ANNUAL CONGRESS 2015 The insulin resistanc</a> <a title="EMJ Urology 3.2 2015 page 29" href="http://viewer.zmags.com/publication/565ee22c?page=29"> and cryptozoospermia remains controversia</a> <a title="EMJ Urology 3.2 2015 page 30" href="http://viewer.zmags.com/publication/565ee22c?page=30"> EAU ANNUAL CONGRESS 2015 Recurrent Urinary Trac</a> <a title="EMJ Urology 3.2 2015 page 31" href="http://viewer.zmags.com/publication/565ee22c?page=31"> innate immune system, which can be har</a> <a title="EMJ Urology 3.2 2015 page 32" href="http://viewer.zmags.com/publication/565ee22c?page=32"> </a> <a title="EMJ Urology 3.2 2015 page 33" href="http://viewer.zmags.com/publication/565ee22c?page=33"> EDITORIAL BOARD INTERVIEWS Evangelos Liatsikos As</a> <a title="EMJ Urology 3.2 2015 page 34" href="http://viewer.zmags.com/publication/565ee22c?page=34"> EDITORIAL BOARD INTERVIEWS encrustation, obstru</a> <a title="EMJ Urology 3.2 2015 page 35" href="http://viewer.zmags.com/publication/565ee22c?page=35"> will develop metastases and eventually die from P</a> <a title="EMJ Urology 3.2 2015 page 36" href="http://viewer.zmags.com/publication/565ee22c?page=36"> EDITORIAL BOARD INTERVIEWS A: While many urologi</a> <a title="EMJ Urology 3.2 2015 page 37" href="http://viewer.zmags.com/publication/565ee22c?page=37"> emission tomography (PET) and magneti</a> <a title="EMJ Urology 3.2 2015 page 38" href="http://viewer.zmags.com/publication/565ee22c?page=38"> EDITORIAL BOARD INTERVIEWS this is not just abou</a> <a title="EMJ Urology 3.2 2015 page 39" href="http://viewer.zmags.com/publication/565ee22c?page=39"> “EAU provides great educational platforms...” Q:</a> <a title="EMJ Urology 3.2 2015 page 40" href="http://viewer.zmags.com/publication/565ee22c?page=40"> EDITORIAL BOARD INTERVIEWS A: The world is becom</a> <a title="EMJ Urology 3.2 2015 page 41" href="http://viewer.zmags.com/publication/565ee22c?page=41"> were comparable to those in adults. Beyond the ou</a> <a title="EMJ Urology 3.2 2015 page 42" href="http://viewer.zmags.com/publication/565ee22c?page=42"> EDITORIAL BOARD INTERVIEWS Riccardo Bartoletti As</a> <a title="EMJ Urology 3.2 2015 page 43" href="http://viewer.zmags.com/publication/565ee22c?page=43"> in the male sexual partners of women. In the same</a> <a title="EMJ Urology 3.2 2015 page 44" href="http://viewer.zmags.com/publication/565ee22c?page=44"> EDITORIAL BOARD INTERVIEWS 45-54 years, while it</a> <a title="EMJ Urology 3.2 2015 page 45" href="http://viewer.zmags.com/publication/565ee22c?page=45"> makes urology an attractive area for indust</a> <a title="EMJ Urology 3.2 2015 page 46" href="http://viewer.zmags.com/publication/565ee22c?page=46"> EDITORIAL BOARD INTERVIEWS developments we have </a> <a title="EMJ Urology 3.2 2015 page 47" href="http://viewer.zmags.com/publication/565ee22c?page=47"> UROLIFT®IS CHANGING BPH SYMPTOM REL</a> <a title="EMJ Urology 3.2 2015 page 48" href="http://viewer.zmags.com/publication/565ee22c?page=48"> Promotional supplement A NEW APPROACH FOR </a> <a title="EMJ Urology 3.2 2015 page 49" href="http://viewer.zmags.com/publication/565ee22c?page=49"> Management of ED: Room for Improvement? P</a> <a title="EMJ Urology 3.2 2015 page 50" href="http://viewer.zmags.com/publication/565ee22c?page=50"> PGE acts on the cAMP pathway 1 The </a> <a title="EMJ Urology 3.2 2015 page 51" href="http://viewer.zmags.com/publication/565ee22c?page=51"> The adverse event (AE) profiles of PDE-5 inhibitor</a> <a title="EMJ Urology 3.2 2015 page 52" href="http://viewer.zmags.com/publication/565ee22c?page=52"> Phase II studies, significant improvements in all </a> <a title="EMJ Urology 3.2 2015 page 53" href="http://viewer.zmags.com/publication/565ee22c?page=53"> As observed in Phase II studies, the majority of </a> <a title="EMJ Urology 3.2 2015 page 54" href="http://viewer.zmags.com/publication/565ee22c?page=54"> the time of selecting treatment for ED. In a stud</a> <a title="EMJ Urology 3.2 2015 page 55" href="http://viewer.zmags.com/publication/565ee22c?page=55"> In contrast, common local AEs with alprostadil cr</a> <a title="EMJ Urology 3.2 2015 page 56" href="http://viewer.zmags.com/publication/565ee22c?page=56"> consequences. BJU Int. 1999;84(1):50-6. 6. Porst </a> <a title="EMJ Urology 3.2 2015 page 57" href="http://viewer.zmags.com/publication/565ee22c?page=57"> NAVIGATING THE mCRPC LANDSCAPE: EXPLORING </a> <a title="EMJ Urology 3.2 2015 page 58" href="http://viewer.zmags.com/publication/565ee22c?page=58"> mortality and can significantly increase the risk </a> <a title="EMJ Urology 3.2 2015 page 59" href="http://viewer.zmags.com/publication/565ee22c?page=59"> patient diagnosed with mCRPC in 20</a> <a title="EMJ Urology 3.2 2015 page 60" href="http://viewer.zmags.com/publication/565ee22c?page=60"> of hormonal therapy the patient experienced </a> <a title="EMJ Urology 3.2 2015 page 61" href="http://viewer.zmags.com/publication/565ee22c?page=61"> metastatic PrC in July 2010. The patient h</a> <a title="EMJ Urology 3.2 2015 page 62" href="http://viewer.zmags.com/publication/565ee22c?page=62"> REFERENCES 1. Saad F et al. The 2015 CUA-CUOG Gu</a> <a title="EMJ Urology 3.2 2015 page 63" href="http://viewer.zmags.com/publication/565ee22c?page=63"> GRESS HIGHLIGHTS · DISCUSSIONS · INTERVIEWS · WEB</a> <a title="EMJ Urology 3.2 2015 page 64" href="http://viewer.zmags.com/publication/565ee22c?page=64"> ABSTRACT SUMMARIES IS THE YOUNG PATIENT A C</a> <a title="EMJ Urology 3.2 2015 page 65" href="http://viewer.zmags.com/publication/565ee22c?page=65"> EAU if necessary. This must be done during the e</a> <a title="EMJ Urology 3.2 2015 page 66" href="http://viewer.zmags.com/publication/565ee22c?page=66"> ABSTRACT SUMMARIES EAU This increased from 2.</a> <a title="EMJ Urology 3.2 2015 page 67" href="http://viewer.zmags.com/publication/565ee22c?page=67"> Histopathological evaluation revealed </a> <a title="EMJ Urology 3.2 2015 page 68" href="http://viewer.zmags.com/publication/565ee22c?page=68"> ABSTRACT SUMMARIES EAU of localised PrC ma</a> <a title="EMJ Urology 3.2 2015 page 69" href="http://viewer.zmags.com/publication/565ee22c?page=69"> Another promising approach will be </a> <a title="EMJ Urology 3.2 2015 page 70" href="http://viewer.zmags.com/publication/565ee22c?page=70"> ABSTRACT SUMMARIES EAU the Gleason score d</a> <a title="EMJ Urology 3.2 2015 page 71" href="http://viewer.zmags.com/publication/565ee22c?page=71"> risk factor for BCR. Both NDSM (hazard ratio [HR]</a> <a title="EMJ Urology 3.2 2015 page 72" href="http://viewer.zmags.com/publication/565ee22c?page=72"> ABSTRACT SUMMARIES EAU RITONAVIR SYNERGISES </a> <a title="EMJ Urology 3.2 2015 page 73" href="http://viewer.zmags.com/publication/565ee22c?page=73"> IMPACT OF FLUORESCENCE-GUIDED </a> <a title="EMJ Urology 3.2 2015 page 74" href="http://viewer.zmags.com/publication/565ee22c?page=74"> ABSTRACT SUMMARIES EAU The 3-year RFS/CSS/OS </a> <a title="EMJ Urology 3.2 2015 page 75" href="http://viewer.zmags.com/publication/565ee22c?page=75"> mortality in the pre-NAC area. This cutoff does </a> <a title="EMJ Urology 3.2 2015 page 76" href="http://viewer.zmags.com/publication/565ee22c?page=76"> ABSTRACT SUMMARIES EAU abc Cumulative Surviva</a> <a title="EMJ Urology 3.2 2015 page 77" href="http://viewer.zmags.com/publication/565ee22c?page=77"> Table 1: Overview of available checkpoint modulat</a> <a title="EMJ Urology 3.2 2015 page 78" href="http://viewer.zmags.com/publication/565ee22c?page=78"> ABSTRACT SUMMARIES EAU the programmed death</a> <a title="EMJ Urology 3.2 2015 page 79" href="http://viewer.zmags.com/publication/565ee22c?page=79"> (pts) with metastatic renal cell carcinoma (mRCC)</a> <a title="EMJ Urology 3.2 2015 page 80" href="http://viewer.zmags.com/publication/565ee22c?page=80"> ABSTRACT SUMMARIES EAU LOWER URINARY TRACT DYS</a> <a title="EMJ Urology 3.2 2015 page 81" href="http://viewer.zmags.com/publication/565ee22c?page=81"> completing the study (51.2%). The autho</a> <a title="EMJ Urology 3.2 2015 page 82" href="http://viewer.zmags.com/publication/565ee22c?page=82"> ABSTRACT SUMMARIES EAU an increased nocturn</a> <a title="EMJ Urology 3.2 2015 page 83" href="http://viewer.zmags.com/publication/565ee22c?page=83"> predictor of DO in male patients with LUTS and wi</a> <a title="EMJ Urology 3.2 2015 page 84" href="http://viewer.zmags.com/publication/565ee22c?page=84"> ABSTRACT SUMMARIES EAU (i.e. exocytosis/endo</a> <a title="EMJ Urology 3.2 2015 page 85" href="http://viewer.zmags.com/publication/565ee22c?page=85"> The rendezvous technique is an effective, combine</a> <a title="EMJ Urology 3.2 2015 page 86" href="http://viewer.zmags.com/publication/565ee22c?page=86"> ABSTRACT SUMMARIES EAU Decisions on furth</a> <a title="EMJ Urology 3.2 2015 page 87" href="http://viewer.zmags.com/publication/565ee22c?page=87"> [CI]: 1.39-3.43) in Group A and 1.92 g/dl (95% CI</a> <a title="EMJ Urology 3.2 2015 page 88" href="http://viewer.zmags.com/publication/565ee22c?page=88"> ABSTRACT SUMMARIES EAU REFERENCES </a> <a title="EMJ Urology 3.2 2015 page 89" href="http://viewer.zmags.com/publication/565ee22c?page=89"> controlled phase 3 studies. J Urol. 2013;190(1):1</a> <a title="EMJ Urology 3.2 2015 page 90" href="http://viewer.zmags.com/publication/565ee22c?page=90"> PUSHING THE LIMITS WITH NANOKNIFE®: A PROM</a> <a title="EMJ Urology 3.2 2015 page 91" href="http://viewer.zmags.com/publication/565ee22c?page=91"> Interview with Prof Jean de la Rosette Prof Jean </a> <a title="EMJ Urology 3.2 2015 page 92" href="http://viewer.zmags.com/publication/565ee22c?page=92"> during the first days) and sexual func</a> <a title="EMJ Urology 3.2 2015 page 93" href="http://viewer.zmags.com/publication/565ee22c?page=93"> Of course, patients nowadays are more concerned a</a> <a title="EMJ Urology 3.2 2015 page 94" href="http://viewer.zmags.com/publication/565ee22c?page=94"> Having said that, is it too soon to conduct healt</a> <a title="EMJ Urology 3.2 2015 page 95" href="http://viewer.zmags.com/publication/565ee22c?page=95"> How do you explain this? I think it is due to two</a> <a title="EMJ Urology 3.2 2015 page 96" href="http://viewer.zmags.com/publication/565ee22c?page=96"> to tissue regeneration as a natural course of the</a> <a title="EMJ Urology 3.2 2015 page 97" href="http://viewer.zmags.com/publication/565ee22c?page=97"> Moreover, while conventional thermal ablation</a> <a title="EMJ Urology 3.2 2015 page 98" href="http://viewer.zmags.com/publication/565ee22c?page=98"> Figure 4: The NanoKnife® generator. (AngioDynamic</a> <a title="EMJ Urology 3.2 2015 page 99" href="http://viewer.zmags.com/publication/565ee22c?page=99"> Table 1: Available clinical data on IRE in locali</a> <a title="EMJ Urology 3.2 2015 page 100" href="http://viewer.zmags.com/publication/565ee22c?page=100"> Table 2: Ongoing/upcoming clinical studies on IRE</a> <a title="EMJ Urology 3.2 2015 page 101" href="http://viewer.zmags.com/publication/565ee22c?page=101"> Prof Emberton also examined the concept of </a> <a title="EMJ Urology 3.2 2015 page 102" href="http://viewer.zmags.com/publication/565ee22c?page=102"> Lancet Oncol. 2012;13(6):622-32. 12. Madersbacher</a> <a title="EMJ Urology 3.2 2015 page 103" href="http://viewer.zmags.com/publication/565ee22c?page=103"> CHEMOTHERAPY AND NEW DRUGS IN P</a> <a title="EMJ Urology 3.2 2015 page 104" href="http://viewer.zmags.com/publication/565ee22c?page=104"> To date, only two studies have evaluated the use </a> <a title="EMJ Urology 3.2 2015 page 105" href="http://viewer.zmags.com/publication/565ee22c?page=105"> is no evidence of superiority of one therapeutic </a> <a title="EMJ Urology 3.2 2015 page 106" href="http://viewer.zmags.com/publication/565ee22c?page=106"> post-docetaxel setting. Docetaxel re-challengi</a> <a title="EMJ Urology 3.2 2015 page 107" href="http://viewer.zmags.com/publication/565ee22c?page=107"> Salvage hormonal therapy with novel agents Abirat</a> <a title="EMJ Urology 3.2 2015 page 108" href="http://viewer.zmags.com/publication/565ee22c?page=108"> research in past decades, since they repres</a> <a title="EMJ Urology 3.2 2015 page 109" href="http://viewer.zmags.com/publication/565ee22c?page=109"> of Clinical Oncology endorsement of the</a> <a title="EMJ Urology 3.2 2015 page 110" href="http://viewer.zmags.com/publication/565ee22c?page=110"> 59. Teva Pharmaceutical Industries. 2015</a> <a title="EMJ Urology 3.2 2015 page 111" href="http://viewer.zmags.com/publication/565ee22c?page=111"> HOLMIUM LASER ENUCLEATION OF THE PROSTATE (HoLE</a> <a title="EMJ Urology 3.2 2015 page 112" href="http://viewer.zmags.com/publication/565ee22c?page=112"> for larger prostates, >80-100 ml, by </a> <a title="EMJ Urology 3.2 2015 page 113" href="http://viewer.zmags.com/publication/565ee22c?page=113"> Table 1: Data relative to patients undergoing HoL</a> <a title="EMJ Urology 3.2 2015 page 114" href="http://viewer.zmags.com/publication/565ee22c?page=114"> without capsular perforation. Both the use </a> <a title="EMJ Urology 3.2 2015 page 115" href="http://viewer.zmags.com/publication/565ee22c?page=115"> Figure 3: Targeted haemostasis of a capsular arte</a> <a title="EMJ Urology 3.2 2015 page 116" href="http://viewer.zmags.com/publication/565ee22c?page=116"> traditional technique of Gilling, and its progres</a> <a title="EMJ Urology 3.2 2015 page 117" href="http://viewer.zmags.com/publication/565ee22c?page=117"> HOLMIUM LASER ENUCLEATION OF THE PROSTATE </a> <a title="EMJ Urology 3.2 2015 page 118" href="http://viewer.zmags.com/publication/565ee22c?page=118"> RESULTS The conversion rate to conventional hosp</a> <a title="EMJ Urology 3.2 2015 page 119" href="http://viewer.zmags.com/publication/565ee22c?page=119"> EVOLVING TECHNIQUES FOR SURGICAL TREATMENT </a> <a title="EMJ Urology 3.2 2015 page 120" href="http://viewer.zmags.com/publication/565ee22c?page=120"> day case. The development of HoLEP provided a via</a> <a title="EMJ Urology 3.2 2015 page 121" href="http://viewer.zmags.com/publication/565ee22c?page=121"> of the long-term outcome of two case series of Gr</a> <a title="EMJ Urology 3.2 2015 page 122" href="http://viewer.zmags.com/publication/565ee22c?page=122"> hyperplasia. J Endourol. 2003;17(2):93-6. 5. Spal</a> <a title="EMJ Urology 3.2 2015 page 123" href="http://viewer.zmags.com/publication/565ee22c?page=123"> EUROPEAN MEDICAL JOURNAL provides influential arti</a> <a title="EMJ Urology 3.2 2015 page 124" href="http://viewer.zmags.com/publication/565ee22c?page=124"> Buyer’s Guide • ACCORDION MEDICAL • ACCU-TEC</a> <a title="EMJ Urology 3.2 2015 page 125" href="http://viewer.zmags.com/publication/565ee22c?page=125"> • LENUS PHARMA • LISA LASER PRODUCTS • LUMENIS </a> <a title="EMJ Urology 3.2 2015 page 126" href="http://viewer.zmags.com/publication/565ee22c?page=126"> SUBSCRIBE TO RECEIVE THE LATEST CATIONS, PUBL</a>